Aperam


FY23 in line; some hopes for recovery (H2 24)?

12/02/24 -"The group released an expected set of results, while it also anticipates a rather similar Q1 24 vs Q3 23. Even if the market is still depressed, particularly in Europe, a stabilisation is welcome and ..."

Pages
62
Language
English
Published on
12/02/24
You may also be interested by these reports :
16/09/25
A strategic buyer enters the scene: thyssenkrupp has received a non-binding bid for its steel division from Jindal Steel International

15/09/25
OUTOKUMPU (ADD ; Finland) has survived the end of the last decade after what looked like a near-death experience. Since that 2021 recovery, the ...

12/09/25
Earlier this week, Anglo American (ADD ; UK), the UK diversified (though copper-heavy; c.50% of gross assets) mining giant convinced Teck Resources ...

10/09/25
Execution time – Downgrade to Add

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO